DED Magnified: A Real-World Case Library - Case 1
Activity Description and Purpose
In this first case of the series, Dr Walter O. Whitley describes the diagnosis and treatment of a patient with dry eye disease due to meibomian gland dysfunction, along with the latest clinical evidence on new treatments for dry eye disease.
This educational activity is intended for ophthalmologists and optometrists.
- Review clinical evidence of approved treatments for dry eye disease
- Design evidence-based treatment plans for persons with meibomian gland dysfunction–associated dry eye disease
|Walter O. Whitley, OD, MBA, FAAO
Director, Optometric Services
Virginia Eye Consultants
Virginia Beach, Virginia
MedEdicus adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been identified and mitigated by MedEdicus prior to the commencement of the activity.
Walter O. Whitley, OD, MBA, is a consultant for Alcon, Aldeyra Therapeutics, Allergan, Apellis Pharmaceuticals, Bruder Healthcare, Dompé US, Inc, Eyenovia, Inc, Heru, Inc, Iveric Bio, Inc, Mediprint, Novartis Pharmaceuticals Corporation, Oyster Point Pharma, Inc, Regener-Eyes, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals; is an advisory board member of Alcon, Allergan, Bausch & Lomb Incorporated, Bruder Healthcare, Oyster Point Pharma, Inc, ScienceBased Health, Tarsus Pharmaceuticals, Inc, and Visus Therapeutics; is on the speakers bureau for Alcon, Allergan, Bausch & Lomb Incorporated, Oyster Point Pharma, Inc, and Sun Pharmaceutical Industries, Inc; and is a contracted researcher for Heru.
This activity was peer reviewed. The peer reviewer has no relevant commercial relationships to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
COPE approved for 0.25 CE credit for optometrists.
COPE Course ID: 88779-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
This activity, COPE Activity Number 127406, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.
The content of this ACCME-/COPE-accredited CME/CE activity was planned and prepared independently by MedEdicus without input from members of an ineligible company.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at email@example.com.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.
This CME/CE activity is copyrighted to MedEdicus LLC ©2023. All rights reserved. 302.2A
- 0.25 AMA PRA Category 1 Credit™
- 0.25 COPE
- 0.25 Participation